Lupus erythematosus
☆ An den 2022 Stiftung Warentest Resultater aus Däitschland war d'Zefriddenheet vum Konsument mam ModelDerm nëmme liicht manner wéi mat bezuelte Telemedizin Konsultatiounen.
Et schéngt wéi e liicht purpurroude Erythem.
De Päiperlekenausschlag deen typesch am Gesiicht erschéngt.
References
Cutaneous lupus erythematosus (CLE) z'identifizéieren an ze klassifizéieren stellt diagnostesch Erausfuerderungen, ënnerscheet et vun systemic lupus erythematosus mat Hautbedeelegung. Rezent Studien werfen Liicht op genetesch, Ëmwelt- an immunologesch Faktoren déi CLE ënnersträichen. Drogeninduktioun ass speziell als ee vun de wichtegsten Trigger fir CLE entstanen. D'Behandlung beinhalt topesch a systemesch Therapien, inklusiv villverspriechend Biologesch (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , mat bewisenen Effizienz a klineschen Studien.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) deckt verschidde Hautproblemer, vun deenen e puer op méi breet Gesondheetsproblemer kënne verbannen. Et ass a verschidden Aarte kategoriséiert, wéi acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE enthält discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus ass eng Grupp vun Autoimmunerkrankungen déi verschidden Deeler vum Kierper beaflosse kënnen. E puer Aarte, wéi systemic lupus erythematosus (SLE) , beaflossen verschidde Organer, anerer, wéi cutaneous lupus erythematosus (CLE) , beaflossen haaptsächlech d'Haut. Mir kategoriséieren verschidden Aarte vu CLE baséiert op enger Mëschung vu klineschen Zeechen, Tissueuntersuchung, a Blutt Tester, awer et gëtt vill Variatioun tëscht Individuen. Hautprobleemer entwéckelen sech dacks wéinst Faktoren wéi Belaaschtung fir Sonneliicht, Fëmmen oder bestëmmte Medikamenter.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
D'Ursaach vum lupus erythematosus ass net kloer. Ënner identeschen Zwillinge, wann een betraff ass, ass et eng 24% Chance datt deen aneren och wäert sinn. Weiblech Geschlechtshormonen, Sonneliicht, Fëmmen, Vitamin D-Mangel a bestëmmte Infektiounen ginn och ugeholl datt se de Risiko erhéijen.
Behandlungen kënnen NSAIDs, Corticosteroiden, Immunosuppressiva, Hydroxychloroquin a Methotrexat enthalen. Och wann Corticosteroiden effektiv sinn, féiert laangfristeg Benotzung zu Nebenwirkungen.